Nature

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

Thirteen patients were treated during study (Table 1). Vaccination was generally well tolerated with the most common toxicity being local induration or erythema at the site of inoculation. Eleven ...

Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...
ascopubs.org

Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience.

Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...
Nasdaq

Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel

NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features ...
ascopubs.org

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia

Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...